XNASNAMS
Market cap2.74bUSD
Dec 23, Last price
25.63USD
1D
0.51%
1Q
64.82%
IPO
157.33%
Name
NewAmsterdam Pharma Company NV
Chart & Performance
P/E
—
P/S
206.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
13m
-86.69%
Net income
-177m
L+737.06%
CFO
-141m
L
Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 12,763 -86.69% | 95,906 | ||
Cost of revenue | 189,195 | 82,606 | 26,315 | |
Unusual Expense (Income) | ||||
NOPBT | (176,432) | 13,300 | (26,315) | |
NOPBT Margin | 13.87% | |||
Operating Taxes | 27 | |||
Tax Rate | ||||
NOPAT | (176,459) | 13,300 | (26,315) | |
Net income | (176,937) 737.06% | (21,138) -42.42% | (36,712) 538.59% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 7,337 | 377,776 | 69,000 | |
BB yield | -0.80% | -182.74% | ||
| Debt | ||||
Debt current | 60 | 62 | 53 | |
Long-term debt | 60 | 174 | 275 | |
Deferred revenue | 1,019 | 4,492 | ||
Other long-term liabilities | 7,788 | 7,053 | ||
Net debt | (340,330) | (438,286) | (53,482) | |
| Cash flow | ||||
Cash from operating activities | (141,218) | 7,972 | (25,164) | |
CAPEX | (24) | (13) | (20) | |
Cash from investing activities | (24) | 715 | (20) | |
Cash from financing activities | 8,912 | 375,177 | 68,990 | |
FCF | (176,416) | 13,346 | (26,493) | |
| Balance | ||||
Cash | 340,450 | 438,522 | 53,092 | |
Long term investments | 718 | |||
Excess cash | 339,812 | 433,727 | 53,810 | |
Stockholders' equity | (302,378) | 484,521 | 49,791 | |
Invested Capital | 599,638 | 62,457 | (2,610) | |
ROIC | 44.45% | |||
ROCE | 2.68% | |||
| EV | ||||
Common stock shares outstanding | 82,162 | 18,966 | 17,751 | |
Price | 11.17 2.48% | 10.90 | ||
Market cap | 917,749 343.93% | 206,732 | ||
EV | 577,419 | (231,554) | ||
EBITDA | (176,383) | 13,372 | (26,301) | |
EV/EBITDA | ||||
Interest | 6,799 | |||
Interest/NOPBT | ||||